Sugi Predict

Sugi Predict / Compounds / SCHEMBL1662622

SCHEMBL1662622

SCHEMBL1662622

O=Cc1cccc(OCCOCc2ccccc2)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 8/20 0.75
▸ MAOB P27338 8/20 0.75
▸ NPC1 O15118 3/20 0.56
▸ RAB9A P51151 3/20 0.56
▸ CCNB2 O95067 1/20 0.56
▸ CDK1 P06493 1/20 0.56
▸ CDK4 P11802 1/20 0.56
▸ CCNB1 P14635 1/20 0.56
▸ CCND1 P24385 1/20 0.56
▸ CCNB3 Q8WWL7 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ TLR4 O00206 1/20 0.52
▸ TLR2 O60603 1/20 0.52
▸ LCK P06239 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2206728 0.93 MAOA (0.73) MAOAMAOBNPC1RAB9ACCNB2
SCHEMBL2207662 0.93 MAOA (0.73) MAOAMAOBNPC1RAB9ACCNB2
SCHEMBL2206938 0.92 MAOA (0.71) MAOAMAOBNPC1RAB9ACCNB2
SCHEMBL20816026 0.87 MAOA (0.77) MAOAMAOBNPC1RAB9ACCNB2
SCHEMBL314161 0.86 MAOB (1.00) MAOAMAOBNPC1RAB9ACCNB2
SCHEMBL29454637 0.86 MAOB (1.00) MAOAMAOBNPC1RAB9ACCNB2
SCHEMBL9059700 0.86 MAOA (0.70) MAOAMAOBNPC1RAB9ACCNB2
SCHEMBL22181586 0.86 MAOA (0.60) MAOAMAOBNPC1RAB9ACCNB2
SCHEMBL15426822 0.86 MAOA (0.60) MAOAMAOBNPC1RAB9ACCNB2
SCHEMBL19871639 0.85 MAOB (0.54) MAOAMAOBNPC1RAB9ACCNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12029708-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2024-07-09 — — US disclosed
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2023-07-13 — — US disclosed
US-11446261-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2022-09-20 — — US disclosed
EP-4029870-A1 TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF GlaxoSmithKline Intellectual Property (No.2) Limited (GB) 2022-07-20 — — EP disclosed
CN-110003253-B Tricyclic benzoxaborole compounds and uses thereof 葛兰素史克知识产权第二有限公司 2022-03-18 — — CN disclosed
EP-3030519-B1 TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE IP NO 2 LTD (GB) 2022-01-05 — — EP disclosed
EP-3030519-B1 TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE IP NO 2 LTD (GB) 2022-01-05 — — EP disclosed
US-11214582-B2 4-substituted benzoxaborole compounds and uses thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2022-01-04 — — US disclosed
US-11214582-B2 4-substituted benzoxaborole compounds and uses thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2022-01-04 — — US disclosed
US-20210077427-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2021-03-18 — — US disclosed
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2012-10-04 — — US disclosed
EP-2491039-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS Cellzome Limited (GB) 2012-08-29 — — EP disclosed
US-20120214852-A1 Alkoxy Compounds for Disease Treatment ACUCELA INC. (US) 2012-08-23 — — US disclosed
US-20120129894-A1 Alkoxy Compounds for Disease Treatment ACUCELA INC. (US) 2012-05-24 — — US disclosed
US-20120122938-A1 Alkoxy Compounds for Disease Treatment ACUCELA INC. (US) 2012-05-17 — — US disclosed
US-7982071-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2011-07-19 — — US disclosed
WO-2011048082-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 — — WO disclosed
US-20090326074-A1 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2009-12-31 — — US disclosed
EP-2091955-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT Acucela, Inc. (US) 2009-08-26 — — EP disclosed
WO-2009045479-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. (US) 2009-04-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12029708-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER MAOA 421/4885MAOB 318/4885NPC1 47/4885
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS JAK1, JAK3, JAK2 MAOA 2122/4885MAOB 1947/4885NPC1 3936/4885
US-20120122938-A1 Alkoxy Compounds for Disease Treatment ALDH1A2, CLN6, AGER MAOA 421/4885MAOB 318/4885NPC1 47/4885
US-20210077427-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER MAOA 421/4885MAOB 318/4885NPC1 47/4885
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER MAOA 443/4885MAOB 332/4885NPC1 47/4885
US-11214582-B2 4-substituted benzoxaborole compounds and uses thereof BRI3BP, CBR3, CYCS MAOA 3021/4885MAOB 647/4885NPC1 2245/4885
US-11446261-B2 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER MAOA 421/4885MAOB 318/4885NPC1 47/4885
US-20120214852-A1 Alkoxy Compounds for Disease Treatment ALDH1A2, CLN6, AGER MAOA 421/4885MAOB 318/4885NPC1 47/4885
US-20090326074-A1 Alkoxy compounds for disease treatment ALDH1A2, CLN6, AGER MAOA 421/4885MAOB 318/4885NPC1 47/4885
US-20120129894-A1 Alkoxy Compounds for Disease Treatment ALDH1A2, CLN6, AGER MAOA 421/4885MAOB 318/4885NPC1 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.